Clinical Trials Browser

Phase 2 × Recruiting × Cisplatin × Clear all

NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Recruiting

Adenocarcinoma of Lung, Lung Neoplasms

NCT06064097 2026-05-27

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT06406465 2026-05-27

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Phase 2 Recruiting

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06274879 2026-05-26

Ablatio

Phase 2 Recruiting

Gastrointestinal

Bile Duct Neoplasms

NCT06535607 2026-05-26

eVOLVE-02

Phase 2 Recruiting

GastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Uterine Cervical Neoplasms

NCT06788912 2026-05-26

MK-3475-01E

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT07111546 2026-05-26

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

Phase 2 Recruiting

Other solid neoplasm

Advanced Solid Tumour

NCT07321912 2026-05-26

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Phase 2 Recruiting

Sarcoma, Ewing, Osteosarcoma

NCT05061550 2026-05-22

NeoCOAST-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05800574 2026-05-22

Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer

Phase 2 Recruiting

Oropharyngeal Neoplasms

NCT06050252 2026-05-22

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

Phase 2 Recruiting

Gastrointestinal

Resectable Intrahepatic Cholangiocarcinoma

NCT06770582 2026-05-22

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

Phase 2 Recruiting

Sinonasal Squamous Cell Carcinoma

NCT07325539 2026-05-22

LIGHT

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT07601737 2026-05-22

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06029270 2026-05-19

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT07195734 2026-05-19

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Phase 2 Recruiting

Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06868836 2026-05-18

Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

Phase 2 Recruiting

Non-squamous Non-small Cell Lung Cancer

NCT07331155 2026-05-18

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

Phase 2 Recruiting

Other solid neoplasm

Advanced Solid Tumour

NCT07497607 2026-05-18

REDUCE-30

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT02734537 2026-05-15

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Phase 2 Recruiting

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT06702033 2026-05-15

MINT-2

Phase 2 Recruiting

Oropharyngeal Neoplasms

NCT06591650 2026-05-14

GCND

Phase 2 Recruiting

GastrointestinalGenitourinary

Gallbladder Cancer Unresectable

NCT04379596 2026-05-13

DG-03

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT07583511 2026-05-13

Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT05351788 2026-05-12

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05541016 2026-05-12

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

Phase 2 Recruiting

Carcinoma, Oropharyngeal Neoplasms

NCT07310784 2026-05-12

A Phase II Trial of LM103 in Advanced Melanoma

Phase 2 Recruiting

Advanced Melanoma

NCT06323239 2026-05-11

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT04671667 2026-05-08

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06445114 2026-05-08

Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

Phase 2 Recruiting

Carcinoma, Oropharyngeal Neoplasms

NCT07569679 2026-05-06

Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT07570849 2026-05-06

Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT03493425 2026-05-05

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

Phase 2 Recruiting

Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7

NCT05681039 2026-05-05

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05118854 2026-05-04

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

Phase 2 Recruiting

Lung Neoplasms

NCT06532279 2026-05-04

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Stomatitis

NCT07030140 2026-05-01

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Phase 2 Recruiting

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT07559045 2026-04-30

Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Phase 2 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05903092 2026-04-29

MOZART

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT06223568 2026-04-28

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

NCT05268614 2026-04-24

Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06536868 2026-04-24

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT05491512 2026-04-23

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

Phase 2 Recruiting

Oropharyngeal Neoplasms

NCT07209189 2026-04-23

(NeoScorch HN)

Phase 2 Recruiting

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

NCT05655949 2026-04-22

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Phase 2 Recruiting

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT06423326 2026-04-22

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06623656 2026-04-21

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Phase 2 Recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT05775159 2026-04-17

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT06477692 2026-04-17

Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy

Phase 2 Recruiting

Head and Neck Neoplasms